Background: It is known that organ transplant recipients have a significantly higher risk for developing cancers, but the association between immunosuppression in organ transplantation and the risk for prostate cancer (PCa) remains unclear. We aimed to assess the evidence regarding the association of solid organ transplantation with PCa risk.

Methods: A literature search of the PubMed, Embase, and Web of Science databases was performed up to March 2019. Combined relative risks (RRs) and 95% confidence intervals (CIs) were calculated by using a fixed-effect or random-effect model.

Results: In total, 26 articles including 33 independent population-based cohort studies with 556,812 recipients and 2,438 PCa cases were identified and included in this meta-analysis. PCa risk in the solid organ transplant recipients did not increase compared with the general population (RR=1.04; 95% CI: 0.90-1.18). Independent analysis of different kinds of organ replacements further indicated immune inhibition in the transplantation of kidney, liver, heart, and lung, and was not associated with elevated PCa risk (RR=0.89; 95% CI: 0.83-0.95; RR=0.61, 95% CI: 0.21-1.02; RR=1.70, 95% CI: 0.88-2.52; RR=0.87, 95% CI: 0.57-1.16, respectively).

Conclusions: This study demonstrated that immunosuppression in solid organ transplant recipients was not associated with higher PCa risk.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797766PMC
http://dx.doi.org/10.21037/tcr.2019.06.03DOI Listing

Publication Analysis

Top Keywords

solid organ
16
organ transplantation
12
organ transplant
12
transplant recipients
12
pca risk
12
association immunosuppression
8
immunosuppression solid
8
prostate cancer
8
cohort studies
8
organ
7

Similar Publications

Introduction: Cytomegalovirus (CMV) is a DNA-containing virus that is widespread worldwide and is of great importance in infectious pathology of children and adults. The aim of this study is to evaluate the prevalence of CMV among children and immunocompromised patients in the Nizhny Novgorod region (central Russia) and to perform a phylogenetic analysis of the identified strains.

Materials And Methods: DNA samples of CMV detected in frequently ill children and adult recipients of solid organs were studied.

View Article and Find Full Text PDF

Hydatid cysts, caused by the parasite, predominantly affect the liver and lungs, but can also impact other organs such as the kidneys, brain, and muscles. Infection occurs when individuals ingest eggs from contaminated food or water, leading to cyst formation primarily in the liver. While hydatid cysts are commonly found in various endemic regions, muscular involvement is rare, particularly in the psoas muscle.

View Article and Find Full Text PDF

analysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells.

World J Gastroenterol

January 2025

Department of Oncology Surgery, Cell Therapy and Organ Transplantation, Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, Seville 41013, Spain.

Background: Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer with varied incidence and epidemiology worldwide. Sorafenib is still a recommended treatment for a large proportion of patients with advanced HCC. Different patterns of treatment responsiveness have been identified in differentiated hepatoblastoma HepG2 cells and metastatic HCC SNU449 cells.

View Article and Find Full Text PDF

Vascularized composite allograft deceased donation in the United States.

Front Transplant

January 2025

Organ Donation Services, New England Donor Services, Waltham, MA, United States.

Vascularized composite allograft (VCA) transplantation represents a significant advancement in reconstructive surgery and offers hope to individuals who experienced congenital disorders or severe tissue injuries to restore physical appearance, function, and enhance quality of life. VCA recovery introduces complexities to conventional solid organ recovery, and there remain concerns regarding the potential impact of VCA recovery on non-VCA organs for transplant. The current retrospective study examines deceased donor characteristics and observed-to-expected (O/E) organ yield ratios for 51 VCA donors recovered in the US between July 4, 2014 and March 31, 2024, compared with a contemporary cohort of non-VCA donors recovered in 2023.

View Article and Find Full Text PDF

Purpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!